# Clinical Trials Data EGFR - Document 115

# Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.

## Clinical Trial: https://clinicaltrials.gov/study/NCT01993784

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histologically confirmed esophageal squamous carcinoma,failed to first or second line chemothrepay\n\* Age 18 to 75 years old\n\* Measurable disease according to the RECIST criteria(diameter of the lesion should be more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image should be less than 15 days before enrollment)\n\* Life expectancy of \u22653 month\n\* Karnofsky performance status \u226580\n\* WBC\\>3,000/mm3, absolute neutrophil count \u22651500/mm3, platelet\\>100,000/mm3, Hb\\>9g/dl\uff0cBilirubin level \\< 1.0 times ULN\uff0cSerum creatinine \\<1.0 times ULN\uff0cALT and AST\\<2.5 times ULN \uff0cAKP \\< 2.5 times ULN \uff0c(\u22645 times ULN in patients with liver metastases)(within 7 days before enrollment)\n\* No sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever\\>38\u2103\uff1b\n\* Normal ECG/cardiac function\n\* Good compliance\n\* Having signed informed consent -\n\nExclusion Criteria:\n\n\* No previous systemic therapy for metastatic esophageal squamous carcinoma\n\* Known hypersensitivity to study drugs\n\* Tumor with length\u226510cm, liver metastasis covers more than 50% of liver,or lung metastasis covers more than 25% of lung\n\* No measurable lesions, eg. pleural fluid and ascites\n\* Only with Other previous malignancy within 5 year, except non-melanoma skin cancer\n\* Heart failure or other sever organ dysfunction, eg. coronary artery disease, myocardial infarction within the last 6 months only Brain or bone metastasis\n\* Chronic diarrhea\n\* Mentally abnormal or disable cognition,including CNS metastasis\n\* Pregnancy or lactation period",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial is specifically for \*\*esophageal squamous carcinoma\*\*. The inclusion criteria do \*\*not\*\* mention anything about EGFR mutations. Therefore, having an EGFR mutation does \*not\* automatically qualify or disqualify a patient. They would need to meet \*all\* other inclusion criteria and \*none\* of the exclusion criteria to be eligible.